The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase III randomized, placebo-controlled clinical trial evaluating the use of adjuvant endocrine therapy with or without one year of everolimus in patients with high-risk, hormone receptor- (HR) positive and HER2-neu-negative breast cancer: SWOG/NSABP S1207.
Mariana Chavez-Mac Gregor
Consultant or Advisory Role - Novartis
William E. Barlow
No relevant relationships to disclose
Ana M. Gonzalez-Angulo
Consultant or Advisory Role - Novartis
Research Funding - Novartis
Priya Rastogi
No relevant relationships to disclose
Eleftherios P Mamounas
Consultant or Advisory Role - Genomic Health
Patricia A. Ganz
No relevant relationships to disclose
Anne Schott
No relevant relationships to disclose
Soonmyung Paik
No relevant relationships to disclose
Danika Lew
No relevant relationships to disclose
Hanna Bandos
No relevant relationships to disclose
Gabriel N. Hortobagyi
Consultant or Advisory Role - Novartis
Research Funding - Novartis